International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers

Mueller, Jennifer J.; Lajer, Henrik; Mosgaard, Berit Jul; Hamba, S. Bach; Morice, Philippe; Gouy, Sébastien; Hussein, Youssef; Soslow, Robert A.; Schlappe, Brooke A.; Zhou, Qin; Iasonos, Alexia; Høgdall, Claus; Leary, Alexandra; O’Cearbhaill, Roisin E.; Abu‐Rustum, Nadeem R.

doi:10.1097/igc.0000000000001263

Cited by 16 publications

(21 citation statements)

References 18 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observe excellent survival across the overall study population (5 year DSS 85.1%, 5 year PFS 82.8%), consistent with previous reports of high survival rates in MOC [ 3 , 18 , 19 ]. A recent Surveillance, Epidemiology and End Results (SEER) analysis of MOC reported a 5 year OS 82.9% in localized disease [ 3 ].…”

Section: Discussionsupporting

confidence: 91%

“…We show that across our MOC cohort, the risk of relapse after reaching 2 and 5 year relapse-free milestones is low (approximately 8% and 6%, respectively). This is in line with other reports suggesting late relapse is uncommon in MOC [ 9 , 19 ]; however, investigators have not typically sought to quantify subsequent risk at specific disease-free time points. While relapse risk is known to reduce over time, quantification of patient risk at specific time points is clinically valuable.…”

Section: Discussionsupporting

confidence: 83%

“…A recent Surveillance, Epidemiology and End Results (SEER) analysis of MOC reported a 5 year OS 82.9% in localized disease [ 3 ]. Similarly, Mueller et al reported 80% PFS in stage I/II MOC [ 19 ]. We report a 5 year DSS of 17.7% in stage III/IV MOC, similar to the 13.9% reported for distantly disseminated disease in the recent SEER analysis.…”

Section: Discussionmentioning

confidence: 98%

“…A number of previous reports have associated clinical features with PFS time [ 3 , 13 , 19 ]; however, there has been limited description of relapsed cases and comparison against relapse-free MOC to identify clinicopathological features over- and under- represented at relapse. We quantify recurrence risk factors by both PFS analysis and direct comparison of relapsed and relapse-free populations.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma

Hollis

Stillie

Hopkins

et al. 2021

Cancers

View full text Add to dashboard Cite

Mucinous ovarian carcinoma (MOC) is a unique form of ovarian cancer. MOC typically presents at early stage but demonstrates intrinsic chemoresistance; treatment of advanced-stage and relapsed disease is therefore challenging. We harness a large retrospective MOC cohort to identify factors associated with recurrence risk and survival. A total of 151 MOC patients were included. The 5 year disease-specific survival (DSS) was 84.5%. Risk of subsequent recurrence after a disease-free period of 2 and 5 years was low (8.3% and 5.6% over the next 10 years). The majority of cases were FIGO stage I (35.6% IA, 43.0% IC). Multivariable analysis identified stage and pathological grade as independently associated with DSS (p < 0.001 and p < 0.001). Grade 1 stage I patients represented the majority of cases (53.0%) and demonstrated exceptional survival (10 year DSS 95.3%); survival was comparable between grade I stage IA and stage IC patients, and between grade I stage IC patients who did and did not receive adjuvant chemotherapy. At 5 years following diagnosis, the proportion of grade 1, 2 and 3 patients remaining disease free was 89.5%, 74.9% and 41.7%; the corresponding proportions for FIGO stage I, II and III/IV patients were 91.1%, 76.7% and 19.8%. Median post-relapse survival was 5.0 months. Most MOC patients present with low-grade early-stage disease and are at low risk of recurrence. New treatment options are urgently needed to improve survival following relapse, which is associated with extremely poor prognosis.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma

Hollis

Stillie

Hopkins

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Mucinous ovarian carcinoma (MOC) is a relatively rare entity among the different histological subtypes of epithelial ovarian cancer (EOC). Primary MOC accounts for approximately 2%–3% of EOC cases 1,2. Although early-stage MOC presents with a good prognosis, the survival of patients with advanced-stage MOC is worse than that of other EOC subtypes, especially those afflicted by the serous subtype (5-year survival: 10.2%–25.7% vs 20.3%–33.6%, respectively) 3–5.…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of preoperative serum CEA in primary mucinous ovarian carcinoma: a retrospective cohort study

Lin

Cao

Shen

2018

CMAR

View full text Add to dashboard Cite

PurposeThe purpose of this study was to evaluate the prognostic significance of preoperative serum carcinoembryonic antigen (CEA) in primary mucinous ovarian carcinoma (MOC).Patients and methodsWe reviewed 57 patients with primary MOC, in whom preoperative serum CEA had been measured. All patients were treated at Peking Union Medical College Hospital between June 1996 and September 2016.ResultsPreoperative serum CEA was elevated (>5.0 ng/mL) in 10 patients (17.5%), with a median serum CEA of 9.6 ng/mL (5.4–111.7 ng/mL). CEA was significantly associated with preoperative serum cancer antigen 125 (P=0.002), surgical debulking status (P=0.015), and tumor stage (P=0.001). Univariate analysis showed that patients with elevated CEA had significantly worse overall survival (OS) than patients with normal CEA (5-year OS: 50.8% vs 91.9%, respectively; P=0.013), but there was no significant difference in progression-free survival between the two groups (P=0.307). Multivariate analysis further demonstrated that advanced stage was an independent prognostic predictor for OS (P=0.002, HR: 15.925, 95% CI: 2.745–92.404).ConclusionElevated preoperative serum CEA was strongly correlated with advanced stage in primary MOC, which may indicate a poorer prognosis. Further investigation of the intrinsic relationship between CEA and primary MOC is now required.

show abstract

A 62-Year-Old Woman With a Large Abdominal Mass

Marano

Carbone

Roviello

2023

JAMA

View full text Add to dashboard Cite

A 62-year-old nulligravida woman had 10 months of progressive abdominal distension, diffuse abdominal pain, and 25-kg weight gain. She had no nausea or vomiting, hematochezia, or stool changes; pelvic and abdominal examination showed a large abdominal mass extending from the epigastrium to the pelvis but no other abnormalities; results of laboratory testing, including cancer antigen levels, were unremarkable. What is the diagnosis and what would you do next?

show abstract

International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers

Abstract: Most patients (74%) presented with stage I disease. Nearly 50% were treated with adjuvant chemotherapy using various regimens across institutions. The PFS outcomes were favorable for those with early-stage disease and lower but acceptable for those who underwent fertility preservation.

Cited by 16 publications

References 18 publications

Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma

Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma

Prognostic significance of preoperative serum CEA in primary mucinous ovarian carcinoma: a retrospective cohort study

A 62-Year-Old Woman With a Large Abdominal Mass

Contact Info

Product

Resources

About